This review synthesizes clinical, genetic, and mechanistic evidence showing that suPAR and related uPAR fragments are strongly associated with kidney, cardiovascular, and metabolic disease risk. It highlights suPAR as a stable biomarker of innate immune activation with potential pathogenic roles, while underscoring major gaps in assay standardization and therapeutic validation.